Naia Rare Diseases Announces Clinical Trial Authorisation (CTA) to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom

November 15, 2017
RICHMOND, CA--(Marketwired - November 15, 2017) - Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases today announced that it has received Clinical Trial Authorisation ("CTA") from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.
Advertisement

You might like